Unknown

Dataset Information

0

Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.


ABSTRACT: OBJECTIVE:To determine the effects of 10 years of enzyme replacement therapy (ERT) in adult patients with Pompe disease, focusing on individual variability in treatment response. METHODS:In this prospective, multicenter cohort study, we studied 30 patients from the Netherlands and France who had started ERT during the only randomized placebo-controlled clinical trial with ERT in late-onset Pompe disease (NCT00158600) or its extension (NCT00455195) in 2005 to 2008. Main outcomes were walking ability (6-minute walk test [6MWT]), muscle strength (manual muscle testing using Medical Research Council [MRC] grading), and pulmonary function (forced vital capacity [FVC] in the upright and supine positions), assessed at 3- to 6-month intervals before and after the start of ERT. Data were analyzed with linear mixed-effects models for repeated measurements. RESULTS:Median follow-up duration on ERT was 9.8 years (interquartile range [IQR] 8.3-10.2 years). At the group level, baseline 6MWT was 49% of predicted (IQR 41%-60%) and had deteriorated by 22.2 percentage points (pp) at the 10-year treatment point (p < 0.001). Baseline FVC upright was 54% of predicted (IQR 47%-68%) and decreased by 11 pp over 10 years (p < 0.001). Effects of ERT on MRC sum score and FVC supine were similar. At the individual level, 93% of patients had initial benefit of ERT. Depending on the outcome measured, 35% to 63% of patients had a secondary decline after ?3 to 5 years. Still, at 10 years of ERT, 52% had equal or better 6MWT and/or FVC upright compared to baseline. CONCLUSIONS:The majority of patients with Pompe disease benefit from long-term ERT, but many patients experience some secondary decline after ?3 to 5 years. Individual variation, however, is considerable. CLASSIFICATION OF EVIDENCE:This study provides Class IV evidence that for the majority of adults with Pompe disease, long-term ERT positively affects, or slows deterioration in, muscle strength, walking ability, and/or pulmonary function.

SUBMITTER: Harlaar L 

PROVIDER: S-EPMC6946483 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7469279 | BioStudies
2012-01-01 | S-EPMC3519647 | BioStudies
2018-01-01 | S-EPMC6285976 | BioStudies
2019-01-01 | S-EPMC6687674 | BioStudies
2018-01-01 | S-EPMC6326992 | BioStudies
2013-01-01 | S-EPMC4015278 | BioStudies
2018-01-01 | S-EPMC5760608 | BioStudies
2019-01-01 | S-EPMC6629586 | BioStudies
1000-01-01 | S-EPMC5155202 | BioStudies
2020-01-01 | S-EPMC7488760 | BioStudies